Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Short Interest Update

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) was the recipient of a significant drop in short interest during the month of February. As of February 13th, there was short interest totaling 20,170 shares, a drop of 91.2% from the January 29th total of 229,817 shares. Based on an average daily trading volume, of 2,263,410 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.0% of the company’s shares are sold short. Currently, 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 2,263,410 shares, the days-to-cover ratio is presently 0.0 days.

Analysts Set New Price Targets

Separately, Zacks Research lowered Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research report on Wednesday, November 19th. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy”.

Daiichi Sankyo Trading Down 0.5%

Shares of OTCMKTS:DSNKY traded down $0.09 during trading hours on Friday, hitting $19.51. 150,069 shares of the company’s stock traded hands, compared to its average volume of 757,964. The firm has a market capitalization of $36.96 billion and a P/E ratio of 17.90. Daiichi Sankyo has a 1 year low of $17.80 and a 1 year high of $28.21. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.69 and a quick ratio of 1.85. The business has a fifty day moving average price of $20.27 and a 200-day moving average price of $22.77.

Daiichi Sankyo (OTCMKTS:DSNKY) last released its quarterly earnings data on Thursday, January 29th. The company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.05. The company had revenue of $3.65 billion during the quarter, compared to analysts’ expectations of $3.88 billion. Daiichi Sankyo had a net margin of 14.83% and a return on equity of 18.64%. Equities analysts expect that Daiichi Sankyo will post 0.73 earnings per share for the current year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.